



# Long Term Care (LTC) Testing


COVID-19

## Employee Registration



Step 1

- Obtain the **Facility license number** from your employer. You are now ready to create your account in the TestDirectly portal.
- Open a browser and redirect to the: [floridaltc.testdirectly.com](http://floridaltc.testdirectly.com) or using your smartphone, scan the QR Code (to the right) to open the browser using your smartphone.
- The following screen will appear:



- Click the **+ Sign up** button in the upper right corner to begin creating your account. The *Create Account* page displays.

Step 2

- Complete the fields as requested and select **Create Account**.


- You will receive an account activation message. If not redirected, go back to the TestDirectly select **Sign in**.

Account activation email has been sent to your email address. Please activate your account and login

Esc : Close

Step 3

- Open your email account (used to create account) and click on the link to verify your account.



- Once your account has been verified, you will receive the Account verified message. Login to complete your profile.

Account verified. Login to complete your profile

Esc : Close

Step 4


- Complete the employee profile.

Step 5

- Once you select Next, you will be redirected to the Order Form screen with your **Laboratory Requisition Form**. Notice all fields are prepopulated for you. From this page, you may:

- Email the form to yourself
- Download and save the form for later access
- Print the form from within the browser

- You may now **Sign Out**.



### Congratulations!

You have successfully registered for the TestDirectly portal. Please take your printed form with you on the day of your test.



# Long Term Care (LTC) Testing

COVID-19

## Accessing Employee Results



Step 1

- Open a browser and redirect to the: [floridaltc.testdirectly.com](http://floridaltc.testdirectly.com) or using your smartphone, scan the QR Code to open the browser using your smartphone.
- The following screen will appear:




Scan me





Step 2

- Click the **Sign in** button in the upper right corner to sign into your account. The *Login* page displays.



View Results

1. Select the **My Results** from the menu to view the My Result screen.
2. Select (click) on the Report result (Negative/Positive/Inclusive) to view a copy of the results.



- Sample copies of the report are below.

RESIDENT, FLORIDA  
 MRN: 1234MRN  
 DOB: 01/01/76 44 yrs  
 Sex: M  
 Physician: MEDICAL DIRECTOR, MD  
 Location: Florida LTCF  
 Copy to: Division of Emergency Preparedness

Collected: 05/16/2020 00:00  
 Received: 05/16/2020  
 Reported: 05/16/2020 14:18

**NORTHWEST LABORATORY**  
 Kelly A Lloyd, MD, Medical Director  
 CLIA: 50D2158817  
 Accession: 10581731  
 Account: 1234ACACCOUNT

PCR Source: Swab, nasopharyngeal  
 Patient Address: 1234 Sunny St, Tallahassee, FL 32389  
 Patient Phone: (850) 617-1111

Test	Result	Reference	Units	Facility
SARS-CoV-2 (COVID-19)	Not Detected	Not Detected		NWL

1. Performed using high-throughput nucleic acid amplification platforms at Northwest Laboratory using either TeqPath™ COVID-19 Combo RT assay or Quidel Lynx® SARS-CoV-2 assay. Both FDA-cleared Emergency Use Authorizations (EUA) assays (details available upon request). TeqPath™ COVID-19 Combo RT assay was validated by ThermoFisher Scientific using nasopharyngeal swab, nasopharyngeal aspirate, and bronchoalveolar lavage samples, and Quidel Lynx® SARS-CoV-2 assay was validated by Quidel Corporation using nasopharyngeal and oropharyngeal swab samples. Other sample types have not been independently validated by Northwest Laboratory but information on preferred and acceptable collection sites and collection procedures may be obtained at the CDC website <https://www.cdc.gov/coronavirus/2019-nCoV/guidelines-clinical-specimens.html>, which is updated frequently. Negative results do not preclude infection with SARS-CoV-2 virus and should not be the sole basis of a patient management decision. In some patients repeat testing at various time points or from various collection sites may be necessary for virus detection. False-negative results may arise from improper sample collection, degradation of viral RNA during transport or storage, the presence of PCR inhibitors, and/or mutation in the SARS-CoV-2 virus. The impact of vaccines, antiviral medications, antibodies, and immunosuppressive or immunosuppressant drugs on assay performance has not been evaluated. Please see CDC website for updated testing algorithms and other information.

End of Report

RESIDENT, FLORIDA  
 MRN: 1234MRN  
 DOB: 01/01/76 44 yrs  
 Sex: M  
 Physician: MEDICAL DIRECTOR, MD  
 Location: Florida LTCF  
 Copy to: Division of Emergency Preparedness

Collected: 05/16/2020 00:00  
 Received: 05/16/2020  
 Reported: 05/16/2020 14:18

**NORTHWEST LABORATORY**  
 Kelly A Lloyd, MD, Medical Director  
 CLIA: 50D2158817  
 Accession: 10581731  
 Account: 1234ACACCOUNT

PCR Source: Swab, nasopharyngeal  
 Patient Address: 1234 Sunny St, Tallahassee, FL 32389  
 Patient Phone: (850) 617-1111

Test	Result	Reference	Units	Facility
SARS-CoV-2 (COVID-19)	POSITIVE	Negative		NWL

1. Performed using high-throughput nucleic acid amplification platforms at Northwest Laboratory using either TeqPath™ COVID-19 Combo RT assay or Quidel Lynx® SARS-CoV-2 assay. Both FDA-cleared Emergency Use Authorizations (EUA) assays (details available upon request). TeqPath™ COVID-19 Combo RT assay was validated by ThermoFisher Scientific using nasopharyngeal swab, nasopharyngeal aspirate, and bronchoalveolar lavage samples, and Quidel Lynx® SARS-CoV-2 assay was validated by Quidel Corporation using nasopharyngeal and oropharyngeal swab samples. Other sample types have not been independently validated by Northwest Laboratory but information on preferred and acceptable collection sites and collection procedures may be obtained at the CDC website <https://www.cdc.gov/coronavirus/2019-nCoV/guidelines-clinical-specimens.html>, which is updated frequently. Negative results do not preclude infection with SARS-CoV-2 virus and should not be the sole basis of a patient management decision. In some patients repeat testing at various time points or from various collection sites may be necessary for virus detection. False-negative results may arise from improper sample collection, degradation of viral RNA during transport or storage, the presence of PCR inhibitors, and/or mutation in the SARS-CoV-2 virus. The impact of vaccines, antiviral medications, antibodies, and immunosuppressive or immunosuppressant drugs on assay performance has not been evaluated. Please see CDC website for updated testing algorithms and other information.

End of Report